Idexx Laboratories (IDXX) Net Income towards Common Stockholders (2009 - 2026)
Idexx Laboratories (IDXX) reported Net Income towards Common Stockholders of $317.15 million for Q3 2026, up 15.5% from $274.61 million a year earlier but down 6.3% from the prior quarter.
Powered by 
Analysis
Idexx Laboratories (IDXX) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Idexx Laboratories' Net Income towards Common Stockholders came in at $1.18 billion, up 15.1% year-over-year; for FY2025, it was $1.06 billion, up 19.3% from FY2024.
- Net Income towards Common Stockholders has increased for three consecutive years, with a five-year compound annual growth rate of 12.7% (FY2020 to FY2025).
- By year, Net Income towards Common Stockholders came in at $887.87 million in FY2024 (+5.1%), $845.04 million in FY2023 (+24.4%), $679.09 million in FY2022 (-8.8%) and $744.85 million in FY2021 (+28.0%).
- Five-year quarterly Net Income towards Common Stockholders spans a low of $131.98 million in Q2 2022 and a high of $338.41 million in Q2 2026.
- Year over year, Net Income towards Common Stockholders has now increased in each of the last nine quarters, with growth averaging 17.1% over the last eight quarters.
- The high point for year-over-year Net Income towards Common Stockholders in five years was Q2 2023 (growth of 69.9%); the low point was Q2 2022 (a decline of 34.9%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $338.41 million (Q2 2026), $278.45 million (Q1 2026) and $248.19 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,224.11 Bn | 1,197.72 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 665.34 Bn | 585.20 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 515.72 Bn | 483.73 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 362.64 Bn | 325.58 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 315.51 Bn | 288.75 Bn | - | - |
| 6 | Astrazeneca | 289.26 Bn | 263.15 Bn | 13.26 Bn | 3.12 Bn |
| 7 | Amgen | 249.20 Bn | 200.85 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 207.48 Bn | 182.59 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.49 Bn | 114.85 Bn | 12.56 Bn | 3.24 Bn |
| 10 | Idexx Laboratories | 53.33 Bn | 52.56 Bn | 764.30 Mn | 317.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 317.15 Mn |
| Jun 30, 2026 | 338.41 Mn |
| Mar 31, 2026 | 278.45 Mn |
| Dec 31, 2025 | 248.19 Mn |
| Sep 30, 2025 | 274.61 Mn |
| Jun 30, 2025 | 293.99 Mn |
| Mar 31, 2025 | 242.68 Mn |
| Dec 31, 2024 | 216.15 Mn |
| Sep 30, 2024 | 232.84 Mn |
| Jun 30, 2024 | 203.30 Mn |
| Mar 31, 2024 | 235.58 Mn |
| Dec 31, 2023 | 194.52 Mn |
| Sep 30, 2023 | 212.23 Mn |
| Jun 30, 2023 | 224.24 Mn |
| Mar 31, 2023 | 214.05 Mn |
| Dec 31, 2022 | 172.21 Mn |
| Sep 30, 2022 | 180.94 Mn |
| Jun 30, 2022 | 131.98 Mn |
| Mar 31, 2022 | 193.97 Mn |
| Dec 31, 2021 | 162.77 Mn |
API Access
Idexx Laboratories Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IDXX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "IDXX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IDXX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();